Durand Nisha, Mallea Jorge, Zubair Abba C
Laboratory Medicine and Pathology and Center for Regenerative Medicine, Mayo Clinic, Jacksonville, FL, 32224, USA.
Department of Medicine, Division of Allergy, Pulmonary and Sleep Medicine, Mayo Clinic, Jacksonville, FL, 32224, USA.
NPJ Regen Med. 2020 Oct 26;5(1):17. doi: 10.1038/s41536-020-00105-z.
The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the end of 2019 in Hubei province China, is now the cause of a global pandemic present in over 150 countries. COVID-19 is a respiratory illness with most subjects presenting with fever, cough and shortness of breath. In a subset of patients, COVID-19 progresses to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), both of which are mediated by widespread inflammation and a dysregulated immune response. Mesenchymal stem cells (MSCs), multipotent stromal cells that mediate immunomodulation and regeneration, could be of potential benefit to a subset of COVID-19 subjects with acute respiratory failure. In this review, we discuss key features of the current COVID-19 outbreak, and the rationale for MSC-based therapy in this setting, as well as the limitations associated with this therapeutic approach.
2019年末，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在中国湖北省出现，如今已在150多个国家引发全球大流行。新型冠状病毒肺炎（COVID-19）是一种呼吸系统疾病，大多数患者表现为发热、咳嗽和呼吸急促。在一部分患者中，COVID-19会发展为低氧性呼吸衰竭和急性呼吸窘迫综合征（ARDS），这两种情况均由广泛的炎症和失调的免疫反应介导。间充质干细胞（MSCs）是介导免疫调节和再生的多能基质细胞，可能对一部分患有急性呼吸衰竭的COVID-19患者有益。在这篇综述中，我们讨论了当前COVID-19疫情的关键特征、在这种情况下基于间充质干细胞治疗的基本原理，以及这种治疗方法的局限性。
Zotero 插件